Cyclacel Pharmaceuticals Reports Second Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- Nasdaq notches record high close as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Citi cuts investment banking analyst program to two years - Bloomberg
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Nasdaq notches record high close as investors focus on earnings
- This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
Cyclacel Pharma (CYCC) Reports Q2 Loss of $0.10
August 11, 2015 4:45 PM EDTCyclacel Pharma (NASDAQ: CYCC) reported Q2 EPS of ($0.10), versus ($0.22) reported last year. Revenue for the quarter came in at $356 thousand, versus $296 thousand reported last year.
For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.
... More


